Generate Biomedicines Stock

generatebiomedicines.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $686.67MM

Generate:Biomedicines, founded in 2018, is a biotechnology company and developer of a generative biology platform that seeks to use AI and machine learning to create pharmaceutical therapies on demand. Through its Generate Platform, the company aims to produce therapies for constantly changing clinical targets, with the goal of reducing the time and money required to respond to medical conditions. Generate:Biomedicines is headquartered in Somerville, Massachusetts.

Register To Buy and Sell Shares

For more details on financing and valuation for Generate Biomedicines, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Generate Biomedicines’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Generate Biomedicines.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Jason Silvers
Chief Financial Officer
Gevorg Grigoryan Ph.D
Co-Founder & Chief Technology Officer
Beth Grous
Chief People Officer
Dimitris Agrafiotis Ph.D
Chief Digital Officer
Alexandra Snyder MD
Chief Medical Officer & Executive Vice President of Research & Development
Michael Nally
Co-Chief Executive Officer
Geoffrey von Maltzahn Ph.D
Co-Founder & Co-Chief Executive Officer
Molly Gibson Ph.D
Co-Founder & Chief Strategy and Innovation Officer
Sean Martin JD
Chief Legal Officer & General Counsel
Noubar Afeyan Ph.D

Frequently Asked Questions About Generate Biomedicines’ Stock

Can you buy Generate Biomedicines’ stock?
Generate Biomedicines is not publicly traded on NYSE or NASDAQ in the U.S. To buy Generate Biomedicines’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Generate Biomedicines’ stock?
Yes, you can sell stock of a private company like Generate Biomedicines. Forge can help you sell your Generate Biomedicines stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Generate Biomedicines’ stock price?
Generate Biomedicines is a privately held company and therefore does not have a public stock price. However, you may access Generate Biomedicines’ private market stock price with Forge Data.
What is Generate Biomedicines’ stock ticker symbol?
Generate Biomedicines does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Generate:Biomedicines Announces Publication of its Chroma Model in Nature: A Transformative Generative AI for Protein Therapeutics
Generate:Biomedicines announced the publication of its Chroma AI model in Nature. The model can program novel proteins with unique properties. The company is also making the model available to the broader research community to accelerate scientific progress in generative biology. The open-source software can help develop novel protein molecules with therapeutic properties, potentially speeding up protein design developments.
Generate Bio raises $273 million to keep growing
Generate Biomedicines, based in Somerville, has raised $273 million in its latest funding round, despite a decline in biotech investments this year. The company, which uses AI for drug discovery, received funding from previous investors including Abu Dhabi Investment Authority and Fidelity Management & Research Company, as well as from new sources. Generate Biomedicines has raised nearly $700m in equity financing since 2020 and plans to use the new capital to bring other drug programs into clinical and preclinical testing stages.
The Week's 10 Biggest Funding Rounds: Databricks And Generate Biomedicines Lead Another AI Surge
Databricks and Generate Biomedicines led the week's 10 largest funding rounds, with the former raising $500m in a Series I round and the latter raising $273m in a Series C round. Other significant funding rounds included Lyten which raised $200m in a Series B round, and EquipmentShare which raised $150m. AI-related startups featured prominently in this week's funding.
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.